Nextgen Biotech plans to launch a program of inbound medical tourism to Russia for patients from the People's Republic of China. Company will offer Chinese citizens treatment of chronic lower limb ischemia with the drug Neovasculgen developed by the company. After the completion of clinical trials of the drug for other indications, domestic and foreign patients will also have the opportunity to be treated in Russia for diabetic foot syndrome and interstitial cystitis.